Dr. Yale Jen joined Laidlaw & Co. in September 2013 as managing director, biotechnology analyst. He has more than 10 years of Wall Street healthcare analyst experience. Prior to joining Laidlaw, he was a senior equity analyst at Roth Capital Partners, focusing on biotechnology. Before that, Jen was a senior equity analyst focusing on biotechnology and Chinese healthcare at Maxim Group. Previously, he was an associate analyst at Rodman and Renshaw and Thomas Weisel Partners, covering large-cap as well as mid- to small-cap biotechnology and specialty pharmaceutical companies. His investment views have been cited in the Wall Street Journal, Bloomberg, Thomson Reuters and Dow Jones Newswire. Before joining Wall Street, Jen spent several years with KPMG Corporate Finance Life Sciences Group and Genesis Group Associates focusing on mergers and acquisitions of healthcare assets, as well as on pipeline optimization for pharmaceutical and biotechnology clients. Jen received his Ph.D. in molecular biology from Cornell Medical School, and his master’s degree in business administration from Rutgers University with a concentration in finance. He holds FINRA licenses 7, 63, 86 and 87.